Tüdőrák: vizsgálatok itt: Dél-Korea

In Dél-Korea 168 Also abroad 2733

168 trials · From ClinicalTrials.gov, checked 2026. november 12.. Ask the study team whether a trial fits you.

1/2. fázisTaking people
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
Where
Busan, Seoul
Életkor
18 év and over
People
320 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05789082 · EU 2023-507171-22-00
1. fázisTaking people
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Where
Gwangmyeong, Seoul
Életkor
19 év and over
People
238 worldwide
Run by
NiKang Therapeutics, Inc.
See details and how to joinNCT06586957
3. fázisTaking people
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Where
Busan, Cheongju-si, Daegu, Seoul
Életkor
18 év and over
People
600 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06793215
3. fázisTaking people
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Where
Cheongju-si, Dongjak-gu, Goyang-si, Haeundae-gu, Seongnam, Seongnam-si, Seoul, Suwon
Életkor
18 év and over
People
680 worldwide
Run by
Pfizer
See details and how to joinNCT07144280 · EU 2025-521281-97-00
3. fázisTaking people
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Where
Cheongju-si, Seongnam, Seoul
Életkor
18 év and over
People
850 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07361497 · EU 2025-523576-23-00
1. fázisTaking people
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
Where
Seoul
Életkor
18 év and over
People
250 worldwide
Run by
Pfizer
See details and how to joinNCT07519655
1/2. fázisTaking people
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Where
Seoul
Életkor
18 év and over
People
952 worldwide
Run by
Genmab
See details and how to joinNCT05579366
3. fázisTaking people
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Where
Cheongju-si, Daegu, Deagu, Gangnam-gu, Goyang-si, Hwasun, Seoul, Suwon, Yangsan
Életkor
18 év and over
People
1264 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06119581 · EU 2023-503412-33-00
1. fázisTaking people
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Where
Goyang-si Gyeonggi-do
Életkor
18 év and over
People
575 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06400472 · EU 2024-511238-11-00
3. fázisTaking people
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Chungcheongbuk-do, Hwasun-gun, Jinju, Jongno -Gu, Seoul, Suwon, Yangsan
Életkor
18 év and over
People
444 worldwide
Run by
Bayer
See details and how to joinNCT06452277 · EU 2024-511319-91-00
1. fázisTaking people
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Where
Seoul
Életkor
18 év and over
People
460 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00
2. fázisTaking people
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Where
Gangnam-Gu, Guro-gu, Hwasun-Eup, Jongno-gu, Seodaemun-gu, Seoul, Suwon
Életkor
18 év and over
People
200 worldwide
Run by
Jazz Pharmaceuticals
See details and how to joinNCT06695845 · EU 2024-516551-41-00
1/2. fázisTaking people
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Where
Seoul
Életkor
18 év and over
People
675 worldwide
Run by
BlossomHill Therapeutics
See details and how to joinNCT06706076
3. fázisTaking people
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Where
Bupyeong-gu, Busan, Cheongju-si, Daegu, Deagu, Eunpyeong-gu, Gangnam-gu, Goyang-si, Hwasun-gun, Nam-gu, Seongnam, Seoul, Suwon, Yangsan
Életkor
18 év and over
People
700 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06890598 · EU 2024-512302-25-00
2. fázisTaking people
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Where
Seoul
Életkor
18 év and over
People
254 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07492680
2. fázisTaking people
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Where
Goyang-si, Seongnam-si, Seoul
Életkor
18 év and over
People
520 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05498428 · EU 2023-505065-91-00
3. fázisTaking people
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Where
Cheongju-si, Daegu, Goyang-si, Seoul, Suwon, Wŏnju
Életkor
18 év and over
People
614 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06170788 · EU 2023-503376-24-00
1/2. fázisTaking people
A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
Where
Seoul
Életkor
18 év and over
People
60 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07227025
2. fázisTaking people
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Where
Cheongju-si, Daegu, Incheon, Seoul, Suwon
Életkor
18 év and over
People
240 worldwide
Run by
Genmab
See details and how to joinNCT07288177 · EU 2025-522107-18-00
2/3. fázisTaking people
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
Where
Daegu, Hwasun, Incheon
Életkor
18 év and over
People
750 worldwide
Run by
Eikon Therapeutics
See details and how to joinNCT07365319 · EU 2025-525013-23-00
2. fázisTaking people
A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
Where
Buk Gu, Busan, Seoul
Életkor
18 év and over
People
68 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07586202
2/3. fázisTaking people
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
Where
Cheongju-si, Daejeon, Goyang-si, Incheon, Jinju, Seongnam-si, Seoul, Suwon
Életkor
18 év and over
People
1580 worldwide
Run by
BioNTech SE
See details and how to joinNCT06712316 · EU 2024-515764-31-00
3. fázisTaking people
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Where
Hwasun, Incheon, Seoul, Suwon
Életkor
18 év and over
People
480 worldwide
Run by
ArriVent BioPharma, Inc.
See details and how to joinNCT07185997
3. fázisTaking people
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Where
Goyang, Seongnam, Seoul, Suwon
Életkor
18 év and over
People
400 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07195695 · EU 2025-521284-12-00
No phaseTaking people
Development and Utilization of an Integrated Clinical Genomic Database
Where
Seoul
People
118 750
Run by
Samsung Medical Center
See details and how to joinNCT07911267